Evonile Pharma Limited

NOVARTIND.BO·BSE·Healthcare
Compare
1,719.85+1.50 (+0.09%)today
At close: Nov 3, 3:57 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close1,718.35
Open1,743.25
Day range1,703.401,743.85
52-week range750.002,588.00
Off day high−1.38%
Off 52-week high−33.55%
Volume794
Avg. volume (3M)9.58K
Market cap42.46B
EPS (TTM)39.61
Forward P/E—
P/E ratio (TTM)43.42
Dividend yield—
Beta (5Y)0.39
Shares outstanding24.69M
Short interest—
Earnings dateMay 9, 2025
Analyst target—
Profit margin26.38%

Against its peers

Compare in full ›
NOVARTIND.BO WINDLAS.NS IOLCP.NS 000739.SZ EVO TEVA
Market cap 42.46B 19.01B 55.50B 25.56B 557.96M 48.81B
P/E (TTM) 43.4 29.5 27.3 31.5 — 97.3
Forward P/E — — 17.5 21.4 -8.3 13.4
Price/book 5.2 3.3 2.9 3.9 0.7 6.1
Dividend yield — 0.72% 0.54% 1.75% — —
1-year change +106.60% −5.35% +102.86% +43.01% −53.73% +71.10%
Today +0.09% +5.47% +2.89% +2.22% +1.29% −0.14%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

News18·Negative

Evonile Pharma posts Rs 77.54 cr net loss in Q2

New Delhi, Nov 3 (PTI) Evonile Pharma, formerly Novartis India, on Tuesday reported a net loss of Rs 77.54 crore in the September quarter, dragged down by exceptional items. The pharma company posted a profit of Rs 24.22 crore in the…

Medical Dialogues··3 outletsPositive

Evonile Pharma Approves Fundraising of Up to Rs 900 Crore Through Rights Issue

Mumbai: Evonile Pharma Limited, formerly known as Novartis India Limited, has approved a proposal to raise funds of up to Rs 900 crore through a rights issue of partly paid-up equity shares. The company’s Board of Directors approved the…

More from 2 other outlets

From the 4Search news index, newest first.

In the news

6mentions in 30 days
6with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance